Chaturvedi Nish, Voight Benjamin F, Wells Jonathan C, Pritlove Cheryl
Unit for Lifelong Health & Ageing, Research Department of Population Science & Experimental Medicine, Institute of Cardiovascular Science, University College London, London, UK.
Department of Systems Pharmacology and Translational Therapeutics, University of Pennsylvania - Perelman School of Medicine, Philadelphia, PA, USA.
Diabetologia. 2025 Aug 7. doi: 10.1007/s00125-025-06516-1.
The global burden of diabetes-across major forms such as type 2 diabetes, type 1 diabetes and gestational diabetes mellitus-disproportionately affects people of non-European ancestry, the majority of whom live in low- and middle-income countries. The heterogeneity of diabetes risks and phenotypes indicates that knowledge derived principally from European-origin populations may not be readily transferable to other groups. In this review our aim is to enhance the quality of diabetes research by championing the inclusion of diverse populations, ensuring clarity of population definition and encouraging exploration of population differences. We review the terminology used to define populations and make recommendations on the use of these terms. We argue that population membership by itself does not determine risks or response to intervention; rather, it is the confluence of genetic, environmental, sociocultural and policy factors that are causal and should be identified. We note that, while common diabetes forms are polygenic and populations are unlikely to harbour single genes that account for significant risk, environmental change that impacts lifestyle and biology demonstrably alters diabetes risk and provides opportunities for effective intervention. Similarly, while genetic variants are associated with adverse events, population group membership may sometimes not be a valid proxy for such variants, which has implications for healthcare equity. For most drugs used in diabetes there is little evidence that drug responsiveness materially differs by population grouping, although it is only recently that well-designed studies have been performed. In contrast, other population characteristics, such as sex, age and obesity, appear to alter glucose-lowering drug effectiveness and should be considered when prescribing. Inclusion of diverse populations in diabetes research, combined with a multidisciplinary approach, is essential if we are to combat the global burden of diabetes.
糖尿病的全球负担——涵盖2型糖尿病、1型糖尿病和妊娠期糖尿病等主要类型——对非欧洲血统人群的影响尤为严重,其中大多数人生活在低收入和中等收入国家。糖尿病风险和表型的异质性表明,主要源自欧洲人群的知识可能无法直接应用于其他群体。在本综述中,我们的目标是通过倡导纳入多样化人群、确保人群定义的清晰性以及鼓励探索人群差异来提高糖尿病研究的质量。我们回顾了用于定义人群的术语,并就这些术语的使用提出建议。我们认为,人群成员身份本身并不能决定风险或对干预的反应;相反,遗传、环境、社会文化和政策因素的共同作用才是导致糖尿病的原因,应该加以识别。我们注意到,虽然常见的糖尿病类型是多基因的,而且人群中不太可能存在单一基因导致显著风险,但影响生活方式和生物学的环境变化显然会改变糖尿病风险,并提供有效干预的机会。同样,虽然基因变异与不良事件有关,但人群组成有时可能不是此类变异的有效代表,这对医疗公平性有影响。对于大多数用于治疗糖尿病的药物,几乎没有证据表明药物反应性在不同人群组之间存在实质性差异,尽管直到最近才进行了精心设计的研究。相比之下,其他人群特征,如性别、年龄和肥胖,似乎会改变降糖药物的疗效,在开处方时应予以考虑。如果我们要应对糖尿病的全球负担,将多样化人群纳入糖尿病研究并采用多学科方法至关重要。